Tom Spurling – Executive Director – Nova Eye Medical (ASX:EYE) is introducing a comprehensive portfolio of novel glaucoma treatment options which span the entire disease process – enabling physicians to intervene earlier, and more often, in the treatment of glaucoma.
Copyright 2023 – Finance News Network
Source: Finance News Network
30 Jul 2021 - Novatti Group Limited (ASX:NOV) CEO, Peter Cook, provides an update on activities from the company's June quarter, discussing growth in platforms and infrastructure and the recent capital raise.
Read More10 Oct 2023 - Andrew Radonjic - Managing Director - Venture Minerals (ASX:VMS) is dedicated to discovering and developing world-class mineral deposits to meet global demand for critical minerals vital to the green energy transition.
Read More16 Aug 2023 - Steven Yatomi Clarke - CEO and Managing Director - Prescient Therapeutics (ASX:PTX) is a clinical-stage biotech company developing personalised medicine approaches to cancer, including targeted and cellular therapies.
Read More27 Aug 2021 - LBT Innovations Limited (ASX:LBT) CEO and Managing Director Brent Barnes provides an update on sales and distribution for the company's Automated Plate Assessment System (APAS), which is used to read culture plates in laboratories.
Read More08 Aug 2023 - BluGlass Limited (ASX:BLG) Non-Executive Director Jean-Michel Pelaprat shines a light on the laser industry.
Read More04 Sep 2019 - Lithium Power International Limited (ASX:LPI) Executive Director - Corporate Finance, Richard Crookes, provides an update on the company's portfolio, starting with its key Maricunga lithium brine project in Northern Chile and hard rock lithium in WA.
Read More21 Jun 2022 - BluGlass Limited (ASX:BLG) President Jim Haden discusses shipping an alpha product to a customer, and the development roadmap for the company.
Read More27 Jun 2022 - North Stawell Minerals Limited (ASX:NSM) CEO Russell Krause discusses recent drilling results, plans through the winter months, and outlook.
Read More31 Mar 2020 - Cynata Therapeutics Limited (ASX:CYP) Managing Director, Dr Ross MacDonald, talks 1H20 results, upcoming Phase 2 clinical trials, licensing and strategy to build the company's Cymerus cell therapy platform.
Read More15 Nov 2022 - OncoSil Medical Limited (ASX:OSL) Non-Executive Director Brian Leedman discusses joining the board of OncoSil and receiving CE mark approval for the company's therapy.
Read More
